meRfi®-GM
Anti-PD-L1 antibodies / PD-L1 inhibitors
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
References (Sources)
- anti-PD1 & anti-PD-L1 checkpoint inhibitors: differences in mechanism of action
- Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancerReview
- Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerationsReview
- Patient selection for anti-PD-1/PD-L1 therapy in advanced NSCLC: implications for clinical practice
- SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti-PD-1-Resistant Model of Non-Small Cell Lung Cancer
- Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health